Meta-Analysis: Superior Treatment Response in Asian Patients with Hepatitis C Virus Genotype 6 versus Genotype 1 with Pegylated Interferon and Ribavirin

Objective: Our goal was to systematically and quantitatively assess treatment response between Asian patients with hepatitis C virus genotype 6 (HCV-6) and hepatitis C virus genotype 1 (HCV-1) treated for 48 weeks with pegylated interferon and ribavirin. Methods: We performed a literature search in MEDLINE and EMBASE for 'genotype 6' in August 2013. Additional abstracts from major international scientific conferences from 2012 to 2013 were reviewed. Studies included were original articles with >= 10 treatment-naive Asian HCV-6 patients. Exclusion criteria were coinfections with hepatitis B virus, HIV and/or other liver diseases. Heterogeneity was defined as a Cochrane Q test with a p value of 0.10 and an I-2 statistic of >50%. Results of a random-effects model are reported. Results: A total of 1,046 (503 HCV-6; 543 HCV-1) patients from I-2 studies were included in the analysis. The pooled sustained virologic response (SVR) rate was 80.2% (95% Cl 74.3-85.0, Q statistic = 20.87, p < 0.035; I-2 =47.3%) for HCV-6 and 62.5% (95% Cl 41.9-79.4, Q statistic = 52.41, p <0.001; I-2 = 92.37) for HCV-1 patients. HCV-6 patients had a significantly higher SVR rate compared to HCV-1 patients (odds ratio 2.73, 95% Cl 1.69-4.41, p < 0.001). Approximately one fourth of patients without early virologic response (EVR) achieved SVR, regardless of genotype (HCV-1, n = 6/23; HCV-6, n = 4/21). Conclusions: Asian patients with HCV-6 can expect higher SVR rates (similar to 80%) than HCV-1 patients (similar to 63%). EVR as a stopping rule is less clear in Asian patients with HCV-6 and HCV-1. (C) 2015 S. Karger AG, Basel